Intensity Therapeutics, INC 10-Q quarterly reports

Intensity Therapeutics reports continued net losses and operational challenges, raising substantial doubt about its ability to continue as a going concern, despite advancements in its clinical trial programs.

Intensity Therapeutics reports a net loss of $2.4 million for Q1 2026, with a significant decrease in R&D expenses due to paused clinical trial enrollments, while cash reserves remain a concern.

Intensity Therapeutics reported a reduced net loss for the nine months ended September 30, 2025, but paused two key clinical trials due to funding constraints and dosing regimen revisions, while raising additional capital to extend its cash runway.

Intensity Therapeutics reported reduced losses but paused its pivotal Phase 3 sarcoma trial due to funding constraints, raising substantial doubt about its ability to continue as a going concern.

Intensity Therapeutics reports a net loss of $3.3 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to limited cash reserves.

Intensity Therapeutics reported a net loss of $13.1 million for the nine months ended September 30, 2024, while progressing its clinical trials for cancer treatments.

Intensity Therapeutics' Q2 2024 report reveals a significant increase in research and development expenses, primarily driven by the initiation of a Phase 3 sarcoma study.

Intensity Therapeutics reported a significant increase in research and development expenses and a net loss of $4.6 million for the first quarter of 2024, as it advances its clinical programs.